Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem raka nerki (typ HLRCC lub papillary)
- •Zaawansowany rak nerki, który można zmierzyć za pomocą badań obrazowych
- •Poprzednio otrzymane maksymalnie 2 rodzaje leczenia na rak nerki, bez wcześniejszego podania bevacizumabu
- •Wiek powyżej 12 lat
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG ≤ 2)
- •Prawidłowe wyniki badań krwi (wystarczająca liczba neutrofili i płytek krwi)
- •Prawidłowe parametry wątroby (bilirubina, transaminazy, fosfataza alkaliczna)
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (13)
UC San Diego Moores Cancer Center
La Jolla, United States
Emory University Hospital Midtown
Atlanta, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, United States
Emory Saint Joseph's Hospital
Atlanta, United States
Northwestern University
Chicago, United States
National Institutes of Health Clinical Center
Bethesda, United States
NCI - Center for Cancer Research
Bethesda, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
NYU Langone Hospital - Long Island
Mineola, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, United States
UT MD Anderson Cancer Center
Houston, United States
Trial contact
Site Public Contact
Mehmet A. Bilen
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Ramaprasad Srinivasan
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.